Ross Lawrenson1,2, Chunhuan Lao3, Leonie Brown3, Lucia Moosa4, Lynne Chepulis3, Rawiri Keenan3, Jacquie Kidd5, Karen Middleton6, Paul Conaglen7, Charles de Groot8, Denise Aitken9, Janice Wong6. 1. Waikato Medical Research Centre, The University of Waikato, Level 3 Hockin building, Waikato Hospital, Hamilton, 3240, New Zealand. Ross.Lawrenson@waikatodhb.health.nz. 2. Strategy and Funding, Waikato District Health Board, Hamilton, New Zealand. Ross.Lawrenson@waikatodhb.health.nz. 3. Waikato Medical Research Centre, The University of Waikato, Level 3 Hockin building, Waikato Hospital, Hamilton, 3240, New Zealand. 4. Midland Cancer Network, Hamilton, New Zealand. 5. Taupua Waiora Research Centre, Auckland University of Technology, Auckland, New Zealand. 6. Respiratory Department, Waikato District Health Board, Hamilton, New Zealand. 7. Waikato Cardiothoracic Unit, Waikato District Health Board, Hamilton, New Zealand. 8. Radiation Oncology, Waikato District Health Board, Hamilton, New Zealand. 9. Respiratory Department, Lake District Health Board, Rotorua, New Zealand.
Abstract
BACKGROUNDS: This study aims to understand the factors that influence whether patients receive potentially curative treatment for early stage lung cancer. A key question was whether indigenous Māori patients were less likely to receive treatment. METHODS: Patients included those diagnosed with early stage lung cancer in 2011-2018 and resident in the New Zealand Midland Cancer Network region. Logistic regression model was used to estimate the odds ratios of having curative surgery/ treatment. The Kaplan Meier method was used to examine the all-cause survival and Cox proportional hazard model was used to estimate the hazard ratio of death. RESULTS: In total 419/583 (71.9%) of patients with Stage I and II disease were treated with curative intent - 272 (46.7%) patients had curative surgery. Patients not receiving potentially curative treatment were older, were less likely to have non-small cell lung cancer (NSCLC), had poorer lung function and were more likely to have an ECOG performance status of 2+. Current smokers were less likely to be treated with surgery and more likely to receive treatment with radiotherapy and chemotherapy. Those who were treated with surgery had a 2-year survival of 87.8% (95% CI: 83.8-91.8%) and 5-year survival of 69.6% (95% CI: 63.2-76.0%). Stereotactic ablative body radiotherapy (SABR) has equivalent effect on survival compared to curative surgery (hazard ratio: 0.77, 95% CI: 0.37-1.61). After adjustment we could find no difference in treatment and survival between Māori and non-Māori. CONCLUSIONS: The majority of patients with stage I and II lung cancer are managed with potentially curative treatment - mainly surgery and increasingly with SABR. The outcomes of those being diagnosed with stage I and II disease and receiving treatment is positive with 70% surviving 5 years.
BACKGROUNDS: This study aims to understand the factors that influence whether patients receive potentially curative treatment for early stage lung cancer. A key question was whether indigenous Māori patients were less likely to receive treatment. METHODS:Patients included those diagnosed with early stage lung cancer in 2011-2018 and resident in the New Zealand Midland Cancer Network region. Logistic regression model was used to estimate the odds ratios of having curative surgery/ treatment. The Kaplan Meier method was used to examine the all-cause survival and Cox proportional hazard model was used to estimate the hazard ratio of death. RESULTS: In total 419/583 (71.9%) of patients with Stage I and II disease were treated with curative intent - 272 (46.7%) patients had curative surgery. Patients not receiving potentially curative treatment were older, were less likely to have non-small cell lung cancer (NSCLC), had poorer lung function and were more likely to have an ECOG performance status of 2+. Current smokers were less likely to be treated with surgery and more likely to receive treatment with radiotherapy and chemotherapy. Those who were treated with surgery had a 2-year survival of 87.8% (95% CI: 83.8-91.8%) and 5-year survival of 69.6% (95% CI: 63.2-76.0%). Stereotactic ablative body radiotherapy (SABR) has equivalent effect on survival compared to curative surgery (hazard ratio: 0.77, 95% CI: 0.37-1.61). After adjustment we could find no difference in treatment and survival between Māori and non-Māori. CONCLUSIONS: The majority of patients with stage I and II lung cancer are managed with potentially curative treatment - mainly surgery and increasingly with SABR. The outcomes of those being diagnosed with stage I and II disease and receiving treatment is positive with 70% surviving 5 years.
Entities:
Keywords:
Lung cancer; Non-small cell lung cancer; Smoking; Stereotactic ablative body radiotherapy; Thoracic surgery
Authors: Martyn P T Kennedy; Leanne Cheyne; Michael Darby; Paul Plant; Richard Milton; Jonathan M Robson; Alison Gill; Puneet Malhotra; Victoria Ashford-Turner; Kirsty Rodger; Elankumaran Paramasivam; Annette Johnstone; Bobby Bhartia; Shishir Karthik; Catherine Foster; Veronica Lovatt; Francesca Hewitt; Louise Cresswell; Victoria H Coupland; Margreet Lüchtenborg; Ruth H Jack; Henrik Moller; Matthew E J Callister Journal: Thorax Date: 2018-06-27 Impact factor: 9.139
Authors: Sahar Mokhles; Naomi Verstegen; Alex P W M Maat; Özcan Birim; Ad J J C Bogers; M Mostafa Mokhles; Frank J Lagerwaard; Suresh Senan; Johanna J M Takkenberg Journal: Lung Cancer Date: 2015-01-15 Impact factor: 5.705
Authors: David C Currow; Hui You; Sanchia Aranda; Brian C McCaughan; Stephen Morrell; Deborah F Baker; Richard Walton; David M Roder Journal: Med J Aust Date: 2014-10-20 Impact factor: 7.738
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Cliff G Robinson; Todd A DeWees; Issam M El Naqa; Kimberly M Creach; Jeffrey R Olsen; Traves D Crabtree; Bryan F Meyers; Varun Puri; Jennifer M Bell; Parag J Parikh; Jeffrey D Bradley Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609
Authors: Margreet Lüchtenborg; Sharma P Riaz; Eric Lim; Richard Page; David R Baldwin; Erik Jakobsen; Peter Vedsted; Mike Lind; Michael D Peake; Anders Mellemgaard; James Spicer; Loic Lang-Lazdunski; Henrik Møller Journal: Thorax Date: 2013-10-30 Impact factor: 9.139